Study title | Year | Intervention | Route of Administration | Cochrane Risk of Bias | Outcome Types | Outcome Measure |
---|---|---|---|---|---|---|
Abdolahi et al. [34] | 2019 | ω-3 fatty acids and nano-curcumin | Oral | Low | Continuous | Attack frequency |
Anand et al. [35] | 2006 | Botox A | Injection | Low | Continuous | Attacks per month |
Ashina et al. [36] | 2020 | Eptinezumab | IV | Low | Continuous, Dichotomous | MMDs |
Aurora et al. [25] | 2007 | Botox A | Injection | Some concerns | Continuous | Episodes per month |
Aurora et al. [37] | 2010 | Botox A | Injection | Low | Continuous | MMDs |
Barrientos & Chana et al. [38] | 2003 | Botox A | Injection | Low | Continuous | Attacks per month |
Bigal et al. [39] | 2015 | Fremanezumab | Injection | Low | Continuous | Headache days |
Bigal et al. [40] | 2015 | Fremanezumab | Injection | Low | Continuous | Migraine days |
Brandes et al. [41] | 2004 | Montelukast | Oral | Low | Continuous, Dichotomous | MMDs, Attack frequency |
Buettner et al. [42] | 2015 | Simvastatin plus vitamin D3 | Oral | Some Concerns | Continuous, Dichotomous | Migraine days |
Cady et al. [43] | 2009 | Carisbamate | Oral | Low | Dichotomous | MMDs |
Casas et al. [44] | 2019 | DAO supplement | Oral | Some concerns | Continuous | Attacks per month |
Chankrachang et al. [45] | 2011 | Botox A | Injection | Low | Continuous | Attacks per month |
Croop et al.[46] | 2021 | Rimegepant | Oral | Low | Continuous, Dichotomous | MMDs |
Detke et al. [47] | 2018 | Galcanezumab | Injection | Low | Continuous, Dichotomous | MHDs |
Diener et al. [48] | 2001 | Cyclandelate | Oral | Low | Continuous | MMDs |
Diener et al. [49] | 2005 | MIG-99 | Oral | Some concerns | Continuous, Dichotomous | Attacks per month, MMDs |
Diener et al. [50] | 2008 | Telmisartan | Oral | High | Continuous, Dichotomous | MMDs |
Diener et al. [51] | 2010 | Botox A | Injection | Low | Continuous | Migraine days |
Diener et al. [52] | 2007 | Topiramate | Oral | Low | Continuous, Dichotomous | MMDs |
Diener et al. [53] | 1996 | Cyclandelate | Oral | Some concerns | Dichotomous | Attack frequency |
Dodick et al. [54] | 2018 | Fremanezumab | Injection | Low | Continuous, Dichotomous | MMDs |
Dodick et al. [55] | 2014 | Eptinezumab | IV | Low | Continuous, Dichotomous | Migraine days, MHDs |
Dodick et al. [56] | 2018 | Erenumab | Injection | Low | Continuous | MMDs |
Dodick et al. [57] | 2014 | Galcanezumab | Injection | Low | Continuous Dichotomous | MHDs, Migraine days |
Dodick et al. [58] | 2019 | Eptinezumab | IV | Low | Dichotomous | MMDs |
Elkind et al. [59] | 2006 | Botox A | Injection | Some concerns | Continuous | Migraine days |
Evers et al. [60] | 2004 | Botox A | Injection | Low | Dichotomous | MMDs |
Ferrari et al. [61] | 2019 | Fremanezumab | Injection | Low | Continuous, Dichotomous | MMDs |
Freitag et al. [29] | 2008 | Botox A | Injection | Low | Continuous, Dichotomous | Episodes per month, MMDs |
Fu et al. [62] | 2012 | Chinese herbal medicine (CXDT-HFG) | Oral | Some concerns | Continuous, Dichotomous | Migraine days |
Gaul et al. [63] | 2015 | Vitamin B2, Magnesium, Coenzyme Q10 | Oral | Low | Continuous | MMDs |
Goadsby et al. [64] | 2017 | Erenumab | Injection | Low | Continuous, Dichotomous | MMDs |
Goadsby et al. [65] | 2009 | Tonabersat | Oral | Some concerns | Continuous, Dichotomous | MMDs, MHDs |
Goadsby et al. [66] | 2020 | Atogepant | Oral | Low | Continuous, Dichotomous | MMDs |
Gonçalves et al. [67] | 2016 | Melatonin, Amitriptyline | Oral | Low | Continuous, Dichotomous | MHDs |
Hajihashemi et al. [68] | 2019 | CoQ10 and L-carnitine | Oral | Some concerns | Continuous | Attack frequency |
Høivik et al.b [31] | 2010 | GW274150 | NA | Low | Dichotomous | MHDs |
Kisler et al. [69] | 2019 | Duloxetine | Oral | High | Continuous | MMDs |
Köseoglu et al. [70] | 2008 | Magnesium | Oral | High | Continuous | Attacks per month |
Lipton et al. [71] | 2011 | Topiramate | Oral | Low | Continuous | MMDs |
Lipton et al. [72] | 2020 | Eptinezumab | IV | Low | Continuous, Dichotomous | MMDs |
Lipton et al. [73] | 2004 | Petasites extract | Oral | Low | Dichotomous | Attack frequency |
Magis et al. [74] | 2007 | Thioctic acid | Oral | Low | Continuous, Dichotomous | Attacks per month, Attack frequency |
Mei et al. [75] | 2004 | Topiramate | Oral | High | Continuous, Dichotomous | MHDs, MMDs |
Millan-Guerrero et al. [76] | 2006 | Histamine | Injection | Some concerns | Continuous | Attack frequency |
Monfared et al. [26] | 2017 | Melatonin | Oral | Low | Continuous | Attack frequency |
Mulleners et al. [77] | 2020 | Galcanezumab | Injection | Low | Continuous, Dichotomous | MHDs |
Noruzzadeh et al. [78] | 2016 | Memantine hydrochloride | Oral | Low | Continuous | Attacks per month |
Ozyalcin et al. [32] | 2005 | Venlafaxine | Oral | High | Continuous | Headache days |
Peikart et al. [79] | 1996 | Magnesium | Oral | High | Continuous, Dichotomous | Migraine days, Attack frequency |
Petri et al. [80] | 2009 | Botox A | Injection | Low | Continuous | Attacks per month |
Pfaffenrath et al. [81] | 2002 | MIG-99 | Oral | Low | Continuous, Dichotomous | Attacks per month, Attack frequency |
Pfaffernath et al. [82] | 1996 | Magnesium | Oral | High | Dichotomous | Intensity and duration |
Pradalier et al. [83] | 2001 | Magnesium | Oral | Some concerns | Continuous | Attacks per month |
Relja et al.a [27] | 2007 | Botox A | Injection | Low | Continuous, Dichotomous | Episodes per month, Migraine episodes per month |
Reuter et al. [84] | 2018 | Erenumab | Injection | Low | Continuous, Dichotomous | MMDs |
Sadeghian et al. [85] | 2015 | Levetiracetam | Oral | High | Dichotomous | Headache attack frequency |
Sakai et al. [86] | 2020 | Galcanezumab | Injection | Low | Continuous, Dichotomous | MHDs |
Sakai et al. [87] | 2021 | Fremanezumab | Injection | Low | Continuous, Dichotomous | MMDs, Headache Days |
Sakai et al. [88] | 2021 | Fremanezumab | Injection | Low | Continuous, Dichotomous | MMDs |
Sakai et al. [89] | 2019 | Erenumab | Injection | Some concerns | Continuous, Dichotomous | MMDs |
Sandor et al. [90] | 2005 | CoQ10 | Oral | Low | Dichotomous | Attack frequency |
Schoenen et al. [91] | 1998 | Riboflavin | Oral | Low | Continuous, Dichotomous | Attacks per month, Attack frequency |
Silberstein et al. [92] | 2020 | Eptinezumab | IV | Low | Continuous, Dichotomous | MMDs |
Silberstein et al. [93] | 2007 | Topiramate | Oral | Some concerns | Continuous | MMDs |
Silberstein et al. [94] | 2006 | Topiramate | Oral | Some concerns | Continuous, Dichotomous | MMDs |
Silbertstein et al. [95] | 2017 | Fremanezumab | Injection | Low | Continuous, Dichotomous | MMDs, Headache days |
Siniatchkin et al. [96] | 1998 | Cyclandelate | Oral | High | Continuous | MMDs |
Siniatchkin et al. [97] | 2007 | Metoprolol-CR | Oral | High | Continuous | Attacks per month |
Skljarevski et al. [98] | 2018 | Galcanezumab | Injection | Low | Continuous, Dichotomous | MMDs, MHDs |
Skljarevski et al. [99] | 2018 | Galcanezumab | Injection | Low | Continuous, Dichotomous | MHDs |
Smith et al. [28] | 2020 | Eptinezumab | IV | Low | Continuous, Dichotomous | MMDs |
Stauffer et al. [100] | 2018 | Galcanezumab | Injection | Low | Continuous, Dichotomous | MHDs |
Steiner et al. [30] | 1998 | S-fluoxetine | Oral | High | Continuous | Attacks per month |
Storey et al. [101] | 2001 | Topiramate | Oral | Some concerns | Continuous, Dichotomous | MMDs |
Sun et al. [102] | 2016 | Erenumab | Injection | Low | Continuous, Dichotomous | MMDs |
Takeshima et al. [103] | 2021 | Erenumab | Injection | Low | Continuous, Dichotomous | MMDs |
Tepper et al. [104] | 2017 | Erenumab | Injection | Low | Continuous, Dichotomous | MMDs |
Trapani et al. [105] | 2000 | Gabapentin | Oral | High | Continuous | Attack frequency |
Vahedi et al. [106] | 2002 | Acetazolamide | Oral | High | Continuous | Attacks per month |
Wang et al. [107] | 2021 | Erenumab | Injection | Low | Continuous, Dichotomous | MMDs |